1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Immuno-Oncology Overview

Immuno-Oncology Overview

  • June 2015
  • -
  • Datamonitor Healthcare

This is an overview of the field of immuno-oncology and the various immuno-oncology classes Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions

Highlights

Datamonitor Healthcare anticipates that the PD-1/PD-L1 class will gain approvals for multiple tumor types, and that this class will be the most commercially successful immuno-oncology class over the next 10 years As monotherapies, PD-1 inhibitors will become the first-line treatment of choice in melanoma, and they are also likely to gain further approvals for a wide variety of cancers

CAR-T cell therapy early clinical results are extremely promising The leading CD19-targeted CAR-T treatments from Novartis, Juno, and Kite all provide response rates hovering around 90% for patients with multiply relapsed or refractory acute lymphoblastic leukemia

Expectations for cancer vaccines have diminished after multiple failures In theory, a cancer vaccine treatment should be able to strengthen the immune response against a cancer and help to prevent it from recurring In practice, a series of Phase III studies investigating cancer vaccines have failed to meet their primary endpoints, and the potential future role of this class has diminished with each trial failure

What’s included in this report?

Three fully transcribed key opinion leader interviews

Coverage of the key immuno-oncology targets include key clinical trial results and a summary of deals related to that class

10-year sales forecasts are included for Yervoy, Opdivo, Keytruda, MEDI4736, and RG7446

Development focus map shows which targets are being investigated by each of the 63 companies with immuno-oncology drugs in development

Key questions answered:

What are the key immuno-oncology products in development?

What important clinical trial results have been reported for drugs in each immuno-oncology drug class?

What specific targets and therapy approaches are the developers in this field focusing on?

What factors could limit the commercial potential of immuno-oncology drugs in development?

What recent deals have taken place that are related to the field of immuno-oncology?






Table Of Contents

Immuno-Oncology Overview
Immuno-oncology overview6
Interviews15
CTLA-425
PD-1/PD-L135
TIM359
LAG363
OX4068
CD40 71
CAR-T cell therapy75
T-cell receptor gene therapy86
Dendritic cell therapy90
CSF1R98
IDO101
CEA 104

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Epiomic Epidemiology Series: Cervical Cancer Forecast in 22 Major Markets 2016 - 2026

Epiomic Epidemiology Series: Cervical Cancer Forecast in 22 Major Markets 2016 - 2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Cervical Cancer in 22 Major Markets Cervical cancer (ICD-10 code C53, cervix uteri) is a type of cancer that occurs in the cells of ...

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025

  • $ 4995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.